Trial Profile
A Randomized Blinded Evaluation of Two Doses of Stavudine (2',3'-Didehydro-2',3'-Dideoxythymidine; d4T) to Make Treatment Available to Severely Immunocompromised Patients With HIV Infection Who Have Failed or Are Intolerant of Alternative Antiretroviral Therapy
Status:
Completed
Phase of Trial:
Clinical Phase Unknown
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Stavudine (Primary)
- Indications HIV infections
- Focus Therapeutic Use
- Sponsors Bristol-Myers Squibb
- 08 Jun 2009 New trial record.